Aoxing Pharma to Announce Fiscal 2015 Financial Results, Host Webcast and Conference Call Oct. 13 at 8:30 AM Eastern

JERSEY CITY, NJ / ACCESSWIRE / October 2, 2015 / Aoxing Pharmaceutical Company, Inc. (NYSE: AXN), a leading China-based pain management company, today said it would announce financial results for its fiscal year 2015, ended June 30, 2015 at 8:30 a.m. Eastern time on Tuesday, October 13, and immediately follow this announcement with a conference call chaired by the company's chairman and chief executive officer, Mr. Zhenjiang Yue, and chief financial officer Mr. Wilfred Chow.

The call will be accessible on the company's website, www.aoxingpharma.com, and via phone conference. Directions for both will be announced prior to the call.

During the call Mr. Chow will discuss Aoxing's performance during fiscal 2015 and the company's plans to grow its core traditional Chinese medicine business as well as develop its new narcotic medicine division in fiscal 2016. Messrs. Yue and Chow will then answer investor questions.

All interested investors are invited to participate in this call.

About the Company

Aoxing Pharmaceutical Company, Inc. is a US incorporated specialty pharmaceutical company with its operations in China, specializing in research, development, manufacturing and distribution of a variety of narcotics and pain-management products. Headquartered in Shijiazhuang City, outside Beijing, Aoxing Pharma has the largest and most advanced manufacturing facility in China for highly regulated narcotic medicines. Its facility is one of the few GMP facilities licensed for the manufacture of narcotic medicines by the China Food and Drug Administration ("CFDA"). For more information, please visit: www.aoxingpharma.com.

Safe Harbor Statement

This press release contains certain statements that may include "forward-looking statements." All statements other than statements of historical fact included herein are "forward-looking statements." These forward-looking statements are often identified by the use of forward-looking terminology such as "believes," "expects" or similar expressions, involving known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks and uncertainties, and these expectations may prove to be incorrect. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including the risk factors discussed in the Company's periodic reports that are filed with the Securities and Exchange Commission and available on the SEC's website (http://www.sec.gov). All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these risk factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.

CONTACT:

Aoxing Pharmaceutical Company:
646-367-1747
investor.relations@aoxingpharma.com

or

Asia IR•PR
Jimmy Caplan, 512-329-9505
jimmy@asia-irpr.com

or

Media Relations:
Asia IR•PR
Rick Eisenberg, 212-496-6828
rick@asia-irpr.com

SOURCE: Aoxing Pharmaceutical Company, Inc

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.